Figure 6. IL-1 activates mTOR pathway through IRAK proteins.

(A) Cell lysates from wild-type, Irak4^−/− and Irak1^−/− Th17 cells untreat ed or treated with IL-1 (10ng/ml) for different time points were analyzed by western blot analysis using antibodies as indicated. (B) Naïve wild-type, Irak4^−/− and Irak1^−/− CD4⁺ T cells (CD4⁺CD44^low) were polarized to Th17 cells (TGFβ+IL-6 on anti-CD3 and anti-CD28 coated plates) in the presence and absence of IL-1β, followed by intracellular cytokine staining for IL-17 and IFN-γ, Error bars, s.d.; *, p<0.05; **.p<0.01 (two tailed t-test). (C) 293 cells transfected with IL-1R (293-IL-1R) cells, IRAK1-deficient cells and 293-IL-1R transfected with SIGIRR were treated or untreated with IL-1 for 15 min. TSC1/TSC2 protein complex was immunoprecipitated and analyzed by western blot analysis using antibodies as indicated. Data are representative of at least three independent experiments.